Sociodemographic and clinical factors associated with prescription of first- versus second-generation long-acting antipsychotics in incarcerated adult males.
Journal
International clinical psychopharmacology
ISSN: 1473-5857
Titre abrégé: Int Clin Psychopharmacol
Pays: England
ID NLM: 8609061
Informations de publication
Date de publication:
02 Oct 2023
02 Oct 2023
Historique:
medline:
2
10
2023
pubmed:
2
10
2023
entrez:
2
10
2023
Statut:
aheadofprint
Résumé
Information on patterns of prescription of long-acting injection (LAI) antipsychotics among people who are incarcerated is lacking. Therefore, we aimed to evaluate prescribing rates for first-generation antipsychotic (FGA)-LAI versus second-generation antipsychotic (SGA)-LAI and to identify the factors associated with the prescription of one of the two classes of LAI. A cross-sectional study was conducted among incarcerated adult males hosted in Monza detention center between January 2013 and April 2023. Socio-demographic and clinical data were retrospectively collected. Descriptive and univariate statistics as well as logistic regression analyses were performed. Data were available for 135 consecutive incarcerated adult males with different mental disorders who received a LAI as part of their treatment. 75.6% of our sample was treated with FGA-LAIs, with haloperidol as the most commonly prescribed drug, followed by zuclopentixol and aripiprazole. Diagnosis of bipolar disorder and concomitant administration of antidepressants were statistically significant predictors of SGA-LAI prescription. Some patients' characteristics may influence prescription patterns in prison. Further longitudinal studies with larger samples should confirm these findings.
Identifiants
pubmed: 37781763
doi: 10.1097/YIC.0000000000000516
pii: 00004850-990000000-00098
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Aass LK, Moen L, Skundberg-Kletthagen H, Lundqvist LO, Schröder A (2022). Family support and quality of community mental health care: perspectives from families living with mental illness. J Clin Nurs 31:935–948.
Altamura AC, Dragogna F (2013). Should the term ‘antipsychotic’ be changed to ‘multidimensional stabiliser’ in bipolar disorder? Towards a new denomination for ‘atypical antipsychotics’. Aust N Z J Psychiatry 47:707–709.
Auxilia AM, Buoli M, Caldiroli A, Carnevali GS, Tringali A, Nava R, et al. (2023). High rate of discontinuation during long-acting injectable antipsychotic treatment in patients with psychotic disorders. Biomedicines 11:314.
Bani-Fatemi A, Tasmim S, Graff A, Gerretsen P, Dada OO, Kennedy JL, et al. (2019). The effect of ethnicity and immigration on treatment resistance in schizophrenia. Compr Psychiatry 89:28–32.
Baranyi G, Fazel S, Langerfeldt SD, Mundt AP (2022). The prevalence of comorbid serious mental illnesses and substance use disorders in prison populations: a systematic review and meta-analysis. Lancet Public Health 7:e557–e568.
Barbui C, Bertolini F, Bartoli F, Calandra C, Callegari C, Carrà G, et al. (2020). Reasons for initiating long-acting antipsychotics in psychiatric practice: findings from the STAR Network Depot Study. Ther Adv Psychopharmacol 10:2045125320978102.
Bartlett A, Dholakia N, England R, Hales H, van Horn E, McGeorge T, et al. (2014). Prison prescribing practice: practitioners’ perspectives on why prison is different. Int J Clin Pract 68:413–417.
Bertolini F, Ostuzzi G, Pievani M, Aguglia A, Bartoli F, Bortolaso P, et al.; STAR Network Investigators (2021). Comparing long-acting antipsychotic discontinuation rates under ordinary clinical circumstances: a survival analysis from an observational, pragmatic study. CNS drugs 35:655–665.
Bhatta MP, Bista S, El Khoury AC, Hutzell EG, Tandon N, Smith D (2021). Long-acting injectable antipsychotic use in patients with schizophrenia and criminal justice system encounters. J Health Econ Outcomes Res 8:63–70.
Buoli M, Ciappolino V, Altamura AC (2015). Paliperidone palmitate depot in the long-term treatment of psychotic bipolar disorder: a case series. Clin Neuropharmacol 38:209–211.
Buoli M, Kahn RS, Serati M, Altamura AC, Cahn W (2016). Haloperidol versus second-generation antipsychotics in the long-term treatment of schizophrenia. Hum Psychopharmacol 31:325–331.
Capuzzi E, Pini E, Malerba MR, Cova F, Lax A, Mauri S, et al. (2019). Factors associated with referrals to high security forensic services among people with severe mental illness and receiving inpatient care in prison. Int J Law Psychiatry 62:90–94.
Capuzzi E, Caldiroli A, Besana F, Cova F, Buoli M, Clerici M (2020). Factors associated with psychotic symptoms among a sample of male people who are incarcerated with substance use disorder: A cross-sectional study. J Subst Abuse Treat 118:108104.
Capuzzi E, Caldiroli A, Besana F, Tagliabue I, Capellazzi M, Cova F, et al. 2021a). The association between childhood trauma and lifetime suicide attempts among a sample of male people who are incarcerated: a pilot observational study. J Forensic Leg Med 80:102180.
Capuzzi E, Ceresa A, Caldiroli A, Esposito CM, Ossola P, Buoli M (2021b). The relation between the plasma concentrations of long-acting atypical antipsychotics and clinical effectiveness in patients affected by schizophrenia or schizoaffective disorder: a comprehensive overview. Curr Pharm Des 27:4070–4077.
Capuzzi E, Capellazzi M, Caldiroli A, Cova F, Auxilia AM, Rubelli P, et al. (2022). Screening for ADHD symptoms among criminal incarcerated people: exploring the association with clinical features. Healthcare (Basel, Switzerland) 10:180.
Carr CN, Hall CP, Roche-Desilets JE, Burant CJ, Fuller MA (2016). Evaluation of adherence in patients prescribed long-acting injectable antipsychotics: a comparison of biweekly versus monthly administered neuroleptics. Ment Health Clin 6:248–253.
Correll CU, Citrome L, Haddad PM, Lauriello J, Olfson M, Calloway SM, et al. (2016). The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence. J Clin Psychiatry 77(Suppl 3):1–24.
DeVylder JE, Lehmann M, Chen FP (2015). Social and clinical correlates of the persistence of psychotic experiences in the general population. Schizophr Res 169:286–291.
von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, et al. (2008). The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 61:344–349.
Esposito CM, Ceresa A, Auxilia AM, Zanelli Quarantini F, Caldiroli A, Capuzzi E, et al. (2022). Which clinical and demographic factors are related to incarceration in male patients with antisocial personality disorder? Int J Offender Ther Comp Criminol:306624X221139073.
Fazel S, Seewald K (2012). Severe mental illness in 33,588 people who are incarcerated worldwide: systematic review and meta-regression analysis. Br J Psychiatry 200:364–373.
Fazel S, Hayes AJ, Bartellas K, Clerici M, Trestman R (2016). Mental health of people who are incarcerated: prevalence, adverse outcomes, and interventions. Lancet Psychiatry 3:871–881.
de Filippis R, Staltari FA, Aloi M, Carbone EA, Rania M, Destefano L, et al. (2023). Effectiveness of SGA-LAIs on clinical, cognitive, and social domains in schizophrenia: results from a prospective naturalistic study. Brain Sci 13:577.
García-Carmona JA, Simal-Aguado J, Campos-Navarro MP, Valdivia-Muñoz F, Galindo-Tovar A (2021). Off-label use of second-generation antipsychotics in borderline personality disorder: a comparative real-world study among oral and long-acting injectables in Spain. Int Clin Psychopharmacol 36:201–207.
Ghio L, Natta W, Gotelli S, Ferrannini L, Research G (2011). Antipsychotic utilisation and polypharmacy in Italian residential facilities: a survey. Epidemiol Psychiatr Sci 20:171–179.
Griffiths EV, Willis J, Spark MJ (2012). A systematic review of psychotropic drug prescribing for people who are incarcerated. Aust N Z J Psychiatry 46:407–421.
Grover S, Sahoo S, Mehra A (2019). Perceptions of psychiatrists toward the use of long-acting injectable antipsychotics: an online survey study from India. J Clin Psychopharmacol 39:611–619.
Hassan L, Edge D, Senior J, Shaw J (2013). Staff and patient perspectives on the purpose of psychotropic prescribing in prisons: care or control? Gen Hosp Psychiatry 35:433–438.
Hassan L, Senior J, Webb RT, Frisher M, Tully MP, While D, et al. (2016). Prevalence and appropriateness of psychotropic medication prescribing in a nationally representative cross-sectional survey of male and female people who are incarcerated in England. BMC Psychiatry 16:346.
Hervás G, Ruano C, Sanz-Alfayate G, Algora I, Celdran MA, Mur MA (2019). Analysis of the management of antipsychotics in a group of prisons. Rev Esp Sanid Penit 21:88–94.
Iasevoli F, Barone A, Buonaguro EF, Vellucci L, de Bartolomeis A (2020). Safety and tolerability of antipsychotic agents in neurodevelopmental disorders: a systematic review. Expert Opin Drug Saf 19:1419–1444.
Kane JM, McEvoy JP, Correll CU, Llorca PM (2021). Controversies surrounding the use of long-acting injectable antipsychotic medications for the treatment of patients with schizophrenia. CNS Drugs 35:1189–1205.
Keepers GA, Fochtmann LJ, Anzia JM, Benjamin S, Lyness JM, Mojtabai R, et al.; (Systematic Review) (2020). The american psychiatric association practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry 177:868–872.
Keramatian K, Chakrabarty T, Yatham LN (2019). Long-acting injectable second-generation/atypical antipsychotics for the management of bipolar disorder: a systematic review. CNS Drugs 33:431–456.
Kirkpatrick T, Joyce E, Milton J, Duggan C, Tyrer P, Rogers RD (2007). Altered emotional decision-making in people who are incarcerated with borderline personality disorder. J Pers Disord 21:243–261.
Koutra K, Triliva S, Roumeliotaki T, Basta M, Simos P, Lionis C, et al. (2015). Impaired family functioning in psychosis and its relevance to relapse: a two-year follow-up study. Compr Psychiatry 62:1–12.
Lian L, Kim DD, Procyshyn RM, Cázares D, Honer WG, Barr AM (2022). Long-acting injectable antipsychotics for early psychosis: a comprehensive systematic review. PLoS One 17:e0267808.
Llorca PM, Abbar M, Courtet P, Guillaume S, Lancrenon S, Samalin L (2013). Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness. BMC Psychiatry 13:340.
Llorca PM, Bobes J, Fleischhacker WW, Heres S, Moore N, Bent-Ennakhil N, et al. (2018). Baseline results from the European non-interventional Antipsychotic Long acTing injection in schizOphrenia (ALTO) study. Eur Psychiatry 52:85–94.
McCreath J, Larson E, Bharatiya P, Labanieh HA, Weiss Z, Lozovatsky M (2017). Long-acting injectable antipsychotics for schizophrenia: sociodemographic characteristics and treatment adherence. Prim Care Companion CNS Disord 19:1.
Mohr P, Knytl P, Voráčková V, Bravermanová A, Melicher T (2017). Long-acting injectable antipsychotics for prevention and management of violent behaviour in psychotic patients. Int J Clin Pract Suppl 71:1.
Nicholls TL, Roesch R, Olley MC, Ogloff JRP, Hemphill JF (2005). Jail Screening Assessment Tool (JSAT): guidelines for mental health screening in jails. Mental health, law, and policy institute, Simon Fraser University.
Nock MK, Borges G, Bromet EJ, Cha CB, Kessler RC, Lee S (2008). Suicide and suicidal behavior. Epidemiol Rev 30:133–154.
Ostuzzi G, Mazzi MA, Terlizzi S, Bertolini F, Aguglia A, Bartoli F, et al.; STAR Network Investigators (2018). Factors associated with first- versus second-generation long-acting antipsychotics prescribed under ordinary clinical practice in Italy. PLoS One 13:e0201371.
Ostuzzi G, Tedeschi F, Bertolini F, Cotugno C, Aguglia A, Bartoli F, et al. (2023). Clinical trajectories of individuals with severe mental illness continuing and discontinuing long-acting antipsychotics: a one-year mirror-image analysis from the STAR Network Depot study. Schizophrenia (Heidelb) 9:23.
Pacchiarotti I, Tiihonen J, Kotzalidis GD, Verdolini N, Murru A, Goikolea JM, et al. (2019). Long-acting injectable antipsychotics (LAIs) for maintenance treatment of bipolar and schizoaffective disorders: a systematic review. Eur Neuropsychopharmacol 29:457–470.
Paton C, Crawford MJ, Bhatti SF, Patel MX, Barnes TR (2015). The use of psychotropic medication in patients with emotionally unstable personality disorder under the care of UK mental health services. J Clin Psychiatry 76:e512–e518.
Pelizza L, Maestri D, Paulillo G, Pellegrini P (2022). Prevalence and appropriateness of antipsychotic prescribing in an Italian prison: is everything always really overprescribed? J Clin Psychopharmacol 42:31–36.
Peritogiannis V, Tsoli F, Gioti P, Bakola M, Jelastopulu E (2023). Use of long-acting injectable antipsychotics in a clinical sample of community-dwelling patients with schizophrenia-spectrum disorders in rural Greece. J Clin Med 12:2508.
Reymann S, Schoretsanitis G, Egger ST, Mohonko A, Kirschner M, Vetter S, et al. (2022). Use of long-acting injectable antipsychotics in inpatients with schizophrenia spectrum disorder in an academic psychiatric hospital in Switzerland. J Pers Med 12:441.
Salvi V, Cerveri G, Aguglia A, Calò S, Corbo M, Martinotti G, et al. (2019). Off-label use of second-generation antipsychotics in bipolar disorder: a survey of italian psychiatrists. J Psychiatr Pract 25:318–327.
Seeman MV (2021). The pharmacodynamics of antipsychotic drugs in women and men. Front Psychiatry 12:650904.
Sheffield JM, Karcher NR, Barch DM (2018). Cognitive deficits in psychotic disorders: a lifespan perspective. Neuropsychol Rev 28:509–533.
Teplin LA (1990). The prevalence of severe mental disorder among male urban jail detainees: comparison with the Epidemiologic Catchment Area Program. Am J Public Health 80:663–669.
Tiihonen J, Mittendorfer-Rutz E, Majak M, Mehtälä J, Hoti F, Jedenius E, et al. (2017). Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with Schizophrenia. JAMA psychiatry 74:686–693.
Tyler N, Miles HL, Karadag B, Rogers G (2019). An updated picture of the mental health needs of male and female prisoners in the UK: prevalence, comorbidity, and gender differences. Soc Psychiatry Psychiatr Epidemiol 54:1143–1152.
Wallace D, Wang X (2020). Does in-prison physical and mental health impact recidivism? SSM Popul Health 11:100569.
Walmsley R (2018). World prison population list. 12th ed. Institute for Criminal Policy Research, London. https://www.prisonstudies.org/sites/default/files/resources/downloads/wppl_12.pdf [Accessed 29 August 2020]
Wang J, Jiang F, Yang Y, Zhang Y, Liu Z, Qin X, et al. (2021). Off-label use of antipsychotic medications in psychiatric inpatients in China: a national real-world survey. BMC psychiatry 21:375.
Weightman M, Kini R, Parker R, Das M (2020). Pharmacological approaches to managing violence and aggression in prison populations: clinical and ethical issues. Drugs 80:1635–1647.
World Health Organization. (1992). The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. World Health Organization.
Yildizhan E, Uzun E, Tomruk NB (2022). Effect of long acting injectable antipsychotics on course and hospitalizations in bipolar disorder - a naturalistic mirror image study. Nord J Psychiatry 76:37–43.
Zarzar TR, Rosen DL, Kane MT, Sheitman BB (2022). The natural history of initial antipsychotic treatment among men admitted to a state prison. Psychiatr Serv 73:1169–1172.